同花顺美股讯 3月21日Cantor Fitzgerald评级报告首次覆盖glycomimetics,首次评级为增持。GLYComimetics于2月13日发布2024年年报,公司截至2024年12月31日,净利润-3787.92万美元,基本每股收益-0.59美元。Glycomimetics, Inc.于2003年在特拉华州成立,是一家后期临床生物技术公司,致力于通过抑制细胞表面发生的碳水化合物...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.